For radioactive iodine-refractory (RAIR) differentiated thyroid cancer, tissue-based biomarker testing to identify actionable alterations (NTRK1/3 fusions, RET fusions, and BRAF V600E mutations) is recommended, with moderate certainty evidence from the American Thyroid Association [31]. The gene discussed is RET; the disease is thyroid gland carcinoma.